Disc Medicine (NASDAQ:IRON) Insider Sells $63,825.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 851 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $75.00, for a total transaction of $63,825.00. Following the transaction, the insider owned 52,173 shares in the company, valued at $3,912,975. The trade was a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Rahul Khara also recently made the following trade(s):

• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total transaction of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Trading Down 1.8%

Shares of Disc Medicine stock traded down $1.36 during trading on Tuesday, reaching $73.14. The company’s stock had a trading volume of 729,507 shares, compared to its average volume of 612,517. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a market cap of $2.79 billion, a price-to-earnings ratio of -11.05 and a beta of 0.93. The firm’s 50-day moving average is $68.99 and its two-hundred day moving average is $70.77. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). On average, sell-side analysts anticipate that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Hedge Funds Weigh In On Disc Medicine

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after acquiring an additional 828,248 shares during the last quarter. BVF Inc. IL purchased a new position in Disc Medicine during the 4th quarter valued at about $51,616,000. Jennison Associates LLC purchased a new position in Disc Medicine during the 4th quarter valued at about $42,252,000. Perceptive Advisors LLC bought a new position in Disc Medicine during the 4th quarter valued at approximately $35,794,000. Finally, RA Capital Management L.P. raised its position in Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on IRON shares. Wells Fargo & Company lifted their price objective on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Wedbush restated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Morgan Stanley boosted their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.